Structural and molecular insight into antibody recognition of dynamic neoepitopes in membrane tethered MUC1 of pancreatic cancer cells and secreted exosomes-Reference-Cited by-同舟云学术

Structural and molecular insight into antibody recognition of dynamic neoepitopes in membrane tethered MUC1 of pancreatic cancer cells and secreted exosomes

Published:2023 Issue:8 Volume:4 Page:564-572
ISSN:2633-0679
Container-title:RSC Chemical Biology
language:en
Short-container-title:RSC Chem. Biol.

Author:

Wakui Hajime¹,Yokoi Yasuhiro¹,Horidome Chieko¹,Ose Toyoyuki²,Yao Min²,Tanaka Yoshikazu³,Hinou Hiroshi¹,Nishimura Shin-Ichiro¹^ORCID

Affiliation:

1. Field of Drug Discovery Research, Faculty of Advanced Life Science, and Graduate School of Life Science, Hokkaido University, N21 W11, Kita-ku, Sapporo, 001-0021, Japan

2. Field of X-ray Structural Biology, Faculty of Advanced Life Science, and Graduate School of Life Science, Hokkaido University, N10 W8, Kita-ku, Sapporo 060-0810, Japan

3. Graduate School of Life Sciences, Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai 980-8577, Japan

Abstract

We unveil for the first time that pancreatic cancer cells (PANC-1) and secreted exosomes express MUC1 bearing cancer-relevant dynamic epitopes recognized specifically by an anti-MUC1 antibody (SN-131).

Funder

Japan Society for the Promotion of Science

Publisher

Royal Society of Chemistry (RSC)

Subject

Biochemistry, Genetics and Molecular Biology (miscellaneous),Molecular Biology,Biochemistry,Chemistry (miscellaneous)

Link

http://pubs.rsc.org/en/content/articlepdf/2023/CB/D3CB00036B

Reference46 articles.

1. Pancreatic cancer

2. Addressing the challenges of pancreatic cancer: Future directions for improving outcomes

3. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

4. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

5. Glycosylation in cancer: mechanisms and clinical implications

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MUC1 and MUC16: critical for immune modulation in cancer therapeutics;Frontiers in Immunology;2024-02-01